What Panazee does

Panazee is a privately held, Berkeley-based health technology company founded in 2021 that has built an ultra-high resolution biomarker platform. The company positions the platform for three end markets: academic and commercial research applications, clinical point-of-care diagnostics, and consumer home testing for personal inner-health monitoring. Its core value proposition is enabling biomarker detection and measurement at high resolution in scenarios where turnaround time matters ("minutes that matter"), suggesting an underlying sensor or assay technology combined with a readout layer rather than purely a software product.

The company operates with a small team of 1–10 employees and is pre-commercial or very early commercial based on available signals: no pricing is publicly disclosed, no customer logos are named, and no management team information is available in the source material. The sole named product is its biomarker platform, with no secondary product lines, mobile app, or API offering documented. Distribution and marketing channels are not specified. Operating status is indicated as active via a live website (panazee.me).

Panazee's business model is not explicitly disclosed. It has secured two early-stage funding rounds in March and April 2022 from Calm/Storm VC and JALE Beteiligungs GmbH, respectively, though disclosed amounts are listed at zero (likely meaning undisclosed rather than literal zero). There is no evidence of revenue, ARR, subscription pricing, hardware sales, or licensing arrangements. Given the absence of pricing details and the breadth of target use cases (research, clinical, consumer), the company appears to still be defining its go-to-market motion.

Name

Panazee

Website

https://panazee.me

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Panazee is a Berkeley-based health technology company, founded in 2021, that has developed an ultra-high resolution biomarker platform targeting academic and commercial research, point-of-care clinical diagnostics, and consumer home health monitoring applications.

Ownership category

akta.pro rank

Product category

Diagnostic Biomarker Platform

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)

Keywords

• Biomarker detection platform
• Point-of-care diagnostics
• Health monitoring technology
• Ultra-high resolution sensing
• Home diagnostic testing

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel

Core offering

Panazee develops an ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision. The platform is intended to serve three application areas: research use in academic and commercial laboratories, point-of-care diagnostic testing in clinical settings, and home-based health monitoring for individual consumers seeking to track their inner health.

Product overview

Panazee offers a single unified product — its ultra-high resolution biomarker platform — which serves research applications, point-of-care diagnostics, and home testing use cases. The platform enables users to monitor their inner health.

Differentiator

Problem solved

Functional benefit

Products and services

• Biomarker Platform Ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision for research applications, point-of-care diagnostics, and home testing. It enables researchers, clinicians, and individual consumers to monitor inner health through biomarker-based analysis.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• Quanterix: Quanterix's Simoa platform offers ultra-sensitive single-molecule biomarker detection for research and diagnostic applications. It is the most directly comparable ultra-high-resolution biomarker technology company to Panazee in both technology positioning and customer base.
• Olink: Olink provides high-sensitivity biomarker analysis platforms (Proximity Extension Assay) for protein biomarker discovery and translational research. It directly competes for the same research-use biomarker platform customers Panazee targets.
• Cytek Biosciences: Cytek provides high-resolution cell-analysis and biomarker profiling instruments for research and clinical flow cytometry. It shares Panazee's positioning around high-resolution, instrumentation-based biomarker measurements in research and translational settings.
• SomaLogic: SomaLogic operates a proteomics biomarker discovery and measurement platform (SomaScan) used by academic and pharma researchers. It is a direct peer to Panazee's research-application biomarker platform business.
• Meso Scale Diagnostics: MSD offers multiplexed electrochemiluminescence biomarker detection platforms widely used in pharma, clinical, and academic research labs. Comparable in instrument-based biomarker workflow to Panazee's platform.

Emerging players

• Healthy.io: Healthy.io turns smartphone cameras into clinical-grade home diagnostic tests (e.g., urinalysis). It overlaps with Panazee's home-testing use case from a consumer diagnostic workflow angle.
• Cue Health: Cue Health developed a molecular at-home diagnostic platform marketed to consumers and point-of-care settings. Comparable to Panazee's home-testing and POC use cases, with a similar small-instrument consumer positioning.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is a global leader in clinical chemistry, immunoassays, and POC diagnostics. It defines the competitive ceiling for biomarker-based clinical diagnostic platforms Panazee would need to clear.
• Bio-Techne: Bio-Techne sells a broad portfolio of research-use biomarker reagents, kits, and instruments (including ProteinSimple platforms). It overlaps with Panazee's research-tools positioning but spans much wider life-sciences reagent categories.
• Abbott Diagnostics: Abbott operates large-scale POC diagnostic platforms (e.g., i-STAT, ARCHITECT) and consumer/biomarker products. It is the incumbent analogue for Panazee's eventual POC and home-testing ambitions.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panazee